Search

AstraZeneca PLC

Suletud

Sektor Tervishoid

12,632 0.45

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

12626

Max

12668

Põhinäitajad

By Trading Economics

Sissetulek

-252M

1.9B

Müük

258M

13B

P/E

Sektori keskmine

38.58

103.001

Aktsiakasum

1.98

Kasumimarginaal

14.894

EBITDA

-349M

4.1B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+5.83 upside

Dividendid

By Dow Jones

Järgmine dividendimakse kuupäev

9. sept 2024

Turustatistika

By TradingEconomics

Turukapital

16M

205B

Eelmine avamishind

12631.55

Eelmine sulgemishind

12632

Uudiste sentiment

By Acuity

61%

39%

296 / 365 Pingereas Healthcare

AstraZeneca PLC Graafik

Seotud uudised

25. juuli 2024, 09:17 UTC

Tulu

AstraZeneca Raises Guidance After Results Beat Market Expectations -- Update

25. juuli 2024, 06:48 UTC

Tulu

AstraZeneca Raises Guidance After Revenue, Earnings Beat Market Expectations

12. juuli 2024, 19:57 UTC

Suurimad hinnamuutused turgudel

Instil Bio Shares Surge Following Rental Agreement with AstraZeneca

5. sept 2024, 13:00 UTC

Peamised uudised

China Detains AstraZeneca Employees Over Alleged Transport of Unapproved Drug -- WSJ

29. juuli 2024, 10:30 UTC

Peamised uudised

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

25. juuli 2024, 13:20 UTC

Tulu

AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook -- IBD

25. juuli 2024, 09:21 UTC

Market Talk
Tulu

AstraZeneca's Guidance Lift Is Conservative; Risks to Upside -- Market Talk

25. juuli 2024, 07:05 UTC

Market Talk
Tulu

AstraZeneca Guidance Raise Signals Portfolio Potential -- Market Talk

25. juuli 2024, 06:06 UTC

Tulu

AstraZeneca Increased Interim Dividend by 7c to $1.00

25. juuli 2024, 06:04 UTC

Tulu

AstraZeneca Had Seen Core EPS Grow by Low Double-Digit to Low Teens Percentage Range

25. juuli 2024, 06:04 UTC

Tulu

AstraZeneca Had Seen Total Revenue Grow by Low Double-Digit to Low Teens Percentage Range

25. juuli 2024, 06:04 UTC

Tulu

AstraZeneca Sees Core EPS Growth in 2024 by Mid Teens Percentage Range At Constant Currency

25. juuli 2024, 06:04 UTC

Tulu

AstraZeneca Sees Total Revenue Growth in 2024 by Mid Teens Percentage Range At Constant Currency

25. juuli 2024, 06:03 UTC

Tulu

AstraZeneca Raises 2024 View

25. juuli 2024, 06:02 UTC

Tulu

AstraZeneca 2Q Revenue Consensus Was $12.7B

25. juuli 2024, 06:02 UTC

Tulu

AstraZeneca 2Q Core EPS Consensus Was $1.95

25. juuli 2024, 06:00 UTC

Tulu

AstraZeneca PLC 2Q Adj EPS $1.98

25. juuli 2024, 06:00 UTC

Tulu

AstraZeneca PLC 2Q Pretax Pft $2.4B

25. juuli 2024, 06:00 UTC

Tulu

AstraZeneca PLC 2Q Rev $12.94B

25. juuli 2024, 06:00 UTC

Tulu

AstraZeneca PLC 2Q Oper Pft $2.75B

25. juuli 2024, 06:00 UTC

Tulu

AstraZeneca PLC 2Q Net Pft $1.93B

25. juuli 2024, 06:00 UTC

Tulu

AstraZeneca PLC 2Q EPS $1.24

15. juuli 2024, 06:04 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone

15. juuli 2024, 06:04 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone

15. juuli 2024, 06:02 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca: Acquisition Includes $800M Upfront at Deal Closing

15. juuli 2024, 06:02 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca: Amolyt Pharma's Total Consideration of Up to $1.05B

15. juuli 2024, 06:01 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca: Acquisition Bolsters Alexion Rare Disease Late-Stage Pipeline

15. juuli 2024, 06:00 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca Completes Acquisition of Amolyt Pharma

15. juuli 2024, 06:00 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca PLC Acquisition of Amolyt Pharma completed

15. juuli 2024, 06:00 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca PLC Acquisition of Amolyt Pharma completed

AstraZeneca PLC Prognoos

Hinnasiht

By TipRanks

5.83% tõus

12 kuu keskmine prognoos

Keskmine 13,271.67 GBX  5.83%

Kõrge 15,000 GBX

Madal 11,000 GBX

Põhineb 15 Wall Streeti analüütiku instrumendi AstraZeneca PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

15 ratings

10

Osta

4

Hoia

1

Müü

Sentiment

By Acuity

296 / 365 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

$

Ettevõttest AstraZeneca PLC

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.